PF-Atlas › Clinical Trials › NCT05428150
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
Esbriet 267 MG Oral Capsule · Phase 1
Registry ID
NCT05428150
Phase
Phase 1
Status
Completed
Drug / intervention
Esbriet 267 MG Oral Capsule
Sponsor
Excalibur Pharmaceuticals, Inc.
Start
2022-08-08
Enrollment
32
Locations
1
About this trial
This is a randomized, open-label, 2-treatment, 2-period, crossover steady state study conducted to evaluate the comparative bioavailability/bioequivalence of pirfenidone after multi-dose administration of EXCL-100 at doses of 1200 mg (600 mg x 2) in the fed state, and Esbriet® 801 mg (267 mg capsule x 3) given in the fed state, to healthy volunteers.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT05428150 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.